Arcus Biosciences, Inc. (RCUS) — Financial statements
Income statement, balance sheet, and cash flow for Arcus Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 247↓4.3% | 258↑120.5% | 117↑4.5% | 112↓70.8% | 383 | |
| Cost of Revenue | 10 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 237↓8.1% | 258↑120.5% | 117↑4.5% | 112↓70.8% | 383 | |
| Operating Expenses | ||||||
| R&D Expenses | 523↑16.7% | 448↑31.8% | 340↑18.1% | 288↑12.1% | 257 | |
| General & Administrative Expenses | 110↓8.3% | 120↑2.6% | 117↑12.5% | 104↑44.4% | 72 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 110↓8.3% | 120↑2.6% | 117↑12.5% | 104↑44.4% | 72 | |
| Other Expenses | -10↓150.0% | 20 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 623↑6.0% | 588↑28.7% | 457↑16.6% | 392↑19.1% | 329 | |
| Total Costs & Expenses | 633↑7.7% | 588↑28.7% | 457↑16.6% | 392↑19.1% | 329 | |
| Operating Results | ||||||
| Operating Income | -386↓17.0% | -330↑2.9% | -340↓21.4% | -280↓618.5% | 54 | |
| Depreciation & Amortization | 10↑0.0% | 10↑25.0% | 8↑33.3% | 6↑50.0% | 4 | |
| EBITDA | -335↓24.5% | -269↑7.6% | -291↓12.8% | -258↓537.3% | 59 | |
| EBIT | -345↓23.7% | -279↑6.7% | -299↓13.3% | -264↓580.0% | 55 | |
| Interest & Other Income | ||||||
| Net Interest Income | -8↓116.7% | 48↑23.1% | 39↑178.6% | 14↑1300.0% | 1 | |
| Interest Income | 0.00↓100.0% | 52↑26.8% | 41↑156.3% | 16↑1500.0% | 1 | |
| Interest Expense | 8↑100.0% | 4↑100.0% | 2↑0.0% | 2 | 0.00 | |
| Non-Operating Income | -41↑19.6% | -51↓24.4% | -41↓156.3% | -16↓1500.0% | -1 | |
| Other Income / Expenses | 33↓29.8% | 47↑20.5% | 39↑178.6% | 14↑1300.0% | 1 | |
| Income Before Tax | -353↓24.7% | -283↑6.0% | -301↓13.2% | -266↓583.6% | 55 | |
| Income Tax Expense | 0.00↓100.0% | 1↓83.3% | 6↑500.0% | 1↓50.0% | 2 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -353↓24.3% | -284↑7.5% | -307↓15.0% | -267↓603.8% | 53 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -353↓24.7% | -283↑7.8% | -307↓15.0% | -267↓603.8% | 53 | |
| Bottom-Line Net Income | -353↓24.7% | -283↑7.8% | -307↓15.0% | -267↓603.8% | 53 | |
| EPS (Basic) | -3.29↓4.8% | -3.14↑24.3% | -4.15↓11.9% | -3.71↓588.2% | 0.76 | |
| EPS (Diluted) | -3.29↓4.8% | -3.14↑24.3% | -4.15↓11.9% | -3.71↓622.5% | 0.71 | |
| Weighted Average Shares | 107↑19.2% | 90↑21.8% | 74↑2.8% | 72↑3.8% | 69 | |
| Weighted Average Diluted Shares | 107↑19.2% | 90↑21.8% | 74↑2.8% | 72↓2.7% | 74 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.